clinical trial · NCT05910528
Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease
Hoffmann-La Roche·phase2·active not recruiting·n = 21
Crohns DiseaseAfimkibart
brief summary
This Phase 2, randomized, double-blind, multicenter, induction and maintenance study is designed to evaluate the safety and efficacy of Afimkibart (RO7790121, RVT-3101) in adult participants with moderate to severe active Crohn's disease.
started
Jul 24, 2023
primary completion
Dec 31, 2030
completion
Dec 31, 2030
last updated
Mar 24, 2026
official title
A Phase 2, Multicenter, Double-blind, Two-arm Study of Subcutaneous RO7790121 for the Treatment of Subjects With Moderate to Severe Active Crohn's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol